Loading…
Generic and specialty pharmaceutical maker producing injectables and generic drugs for the US, Europe and MENA.
Generic and specialty pharmaceutical maker producing injectables and generic drugs for the US, Europe and MENA.
Injectables sold mostly to US hospitals through purchasing groups and wholesalers carry the group, with generic pills and a branded range sold by its own sales force in the Middle East and North Africa making up the rest. Founded in Jordan, it is still led by the Darwazah family, and the US is its biggest market.
In one line: A UK/MENA Teva Pharmaceutical peer.
Moat: narrow (scale, regulatory licence, distribution). Approved manufacturing sites and a leading MENA branded-generics distribution network.
Headquarters: London, UK · Founded: 1978 · Employees: 9,400
Size Hikma Pharmaceuticals (HIK.L) is a United Kingdom Health Care company (Pharmaceuticals: Generic) with a market value of $4.59B, the 100th largest of 363 United Kingdom companies the cockpit tracks. Shares closed at £1,650 on 6 Nov 2026.
Performance Over six months the shares gained 17.7%, against -11.0% for the median peer and +3.6% for the United Kingdom market (cap-weighted) — 3rd highest of 9 in its peer set.
Growth Revenue grew 2.5% over the last twelve months (peer median -3.8%); the operating margin is 19.6% (peer median 0.5%).
Valuation It trades at 9.9× forward earnings against a peer median of 32.3× (cheapest of 5).
Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -5 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.1 points above its cost of capital (8.7% WACC).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | £2.55B | £2.54B | £2.45B | £2.31B | £2.04B |
| Revenue growth | — | +4% | +6% | +13% | — |
| Gross profit | £1.06B | £1.04B | £1.04B | £1.07B | £952M |
| EBITDA | £668M | £592M | £629M | £549M | £565M |
| Net income | £288M | £305M | £281M | £153M | £153M |
| Free cash flow | £110M | £123M | £253M | £293M | £265M |
| Capital expenditure | £218M | £241M | £184M | £164M | £183M |
| Total debt | n/a | £1.19B | £1.04B | £934M | £1.07B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Hikma Pharmaceuticals HIK.L | $4.59B | +18% | +2% | 20% | 9.9× | 1.4% |
| Teva Pharmaceutical Industries Limited Sponsored ADR TEVA | $49.7B | +19% | -4% | 19% | 15.1× | 10.2% |
| Viatris VTRS | $22.9B | +17% | +5% | 10% | 7.5× | 12.5% |
| Sandoz SDZ.SW | $44.4B | +24% | +1% | 15% | 25.3× | 7.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | HIK.L | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.7% | -9.7% | 3rd highest of 9 |
| 6-month return | +17.7% | -11.0% | 3rd highest of 9 |
| Distance from 52-week high | -6.4% | -40.1% | 3rd highest of 9 |
| Revenue growth (TTM) | +2.5% | -3.8% | 4th highest of 9 |
| Operating margin | 19.6% | 0.5% | 2nd highest of 8 |
| Forward P/E | 9.9× | 32.3× | cheapest of 5 |
| Growth the price implies (Req g, 7 yrs) | 1.4% | 17.7% | least demanding of 4 |
| Growth delivered (Del g) | +6.8% | +1.0% | highest of 4 |
| Hurdle (Req g minus delivered) | -5.4 pp | +14.9 pp | least demanding of 4 |
| ROIC minus cost of capital | +3.1 pp | -3.5 pp | 4th highest of 8 |
| EV / EBITDA | 7.0× | n/a | — |
| Net debt / EBITDA | 1.9× | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hikma Pharmaceuticals HIK.L | United Kingdom | $4.59B | +18% | +2% | 20% | 9.9× | 1.4% | +6.8% |
| Haisco Pharmaceutical 002653.SZ | China | $10.0B | +1% | +42% | 18% | 39.3× | 20.5% | +5.7% |
| Neuren Pharmaceuticals NEU.AX | Australia | $2.04B | +83% | -68% | 20% | 39.5× | n/a | n/a |
| Vigonvita Life Sciences 2630.HK | Hong Kong | $1.48B | -11% | +763% | -327% | n/a | n/a | n/a |
| Suzhou Ribo Life Science 6938.HK | Hong Kong | $939M | -29% | +4% | -187% | n/a | n/a | n/a |
| Realcan Pharmaceutical 002589.SZ | China | $628M | -11% | -4% | 0% | n/a | 17.7% | -23.1% |
| Tibet Duo Rui Pharmaceutical 301075.SZ | China | $552M | -45% | -6% | -34% | n/a | n/a | n/a |
| Teva Pharmaceutical Industries Limited Sponsored ADR TEVA | United States | $49.7B | +19% | -4% | 19% | 15.1× | 10.2% | +1.0% |
| Zhejiang Shouxiangu Pharmaceutical 603896.SS | China | $398M | -22% | -10% | n/a | 25.4× | n/a | n/a |